0ABW.L
EGETIS THERAPEUTICS AB (PUBL) E
£5.97
+0.00%
2026-05-28
About EGETIS THERAPEUTICS AB (PUBL) E
Egetis Therapeutics AB (publ), a pharmaceutical company, engages in the development and commercialization of orphan drugs in Sweden and internationally. It develops Aladote, which is in Phase IIb/III clinical trial for the treatment of paracetamol/acetaminophen overdosing and for the prevention of acute liver failure in paracetamol poisoning; and Emcitate, which is in Phase IIb clinical trial for the treatment of monocarboxylate transporter 8 deficiency. The company was formerly known as PledPharma AB (publ) and changed its name to Egetis Therapeutics AB (publ) in December 2020. Egetis Therapeutics AB (publ) was incorporated in 2006 and is headquartered in Stockholm, Sweden.
Key Fundamentals
ROE
-109.7%
Revenue Growth (YoY)
5.5%
Profit Margin
0.0%
Debt/Equity
30.25
Price/Book
9.49
Beta
0.76
Avg Volume (10D)
1K
Recent Breakout Signals
No recent breakout signals detected for 0ABW.L.
Recent Price Range (60 Days)
60D High
£6.96
60D Low
£4.41
Avg Volume
44K
Latest Close
£5.97
Get breakout alerts for 0ABW.L
Sign up for Breakout Scanner to receive daily notifications when 0ABW.L triggers breakout signals. Build custom AI screeners and backtest strategies.
Start Free Trial7-day free trial.
EGETIS THERAPEUTICS AB (PUBL) E (0ABW.L) is listed on the London Stock Exchange (LSE). Breakout Scanner monitors 0ABW.L daily for breakout patterns including long-term ceiling breakouts, momentum breakouts, and near-breakout watch setups.. Data is provided for informational purposes only and does not constitute financial advice.